Authors
Latest:
Evaluating Options for Second-Line HR+, HER2- Breast Cancer TreatmentKatherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.
Latest:
Jessica MacIntyre on Improving LLS Referrals For Patients With Hematologic MalignanciesJessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.
Latest:
Proactive Care in ALK+ NSCLC: AE Counseling, Monitoring, and ManagementPanelists discuss how proactive monitoring for ALK inhibitor adverse effects through regular lipid panels, liver function tests, and patient education about red flag symptoms such as bradycardia or cognitive changes enables early intervention and successful dose management.
Latest:
Unmet Needs and Future Perspectives on the treatment of R/R MMExperts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.
Latest:
Verina on Tackling Neurological Toxicities From CAR T-Cell TherapyDaniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.
Latest:
Nivolumab Combo for RCC Necessitates AE Monitoring, AwarenessAccording to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.
Latest:
Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast CancerUpdates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.
Latest:
Rx Road Map: Durvalumab for Non-Small Cell Lung CancerRead Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.
Latest:
Life After CAR T Therapy: Insights for Patients and Referring OncologistsThis video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.
Latest:
Supporting the Novice Oncology NP: The Benefits of PreceptorshipStructured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.
Latest:
Patient-Centered Approaches in EGFR-Mutated NSCLCPanelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Latest:
Immediate Interventions to Support The Newly BereavedWhen engaging with a family member of a patient who has died, nurses should consider using immediate interventions aimed at supporting the loved ones who are in shock and in pain following their loss.
Latest:
Jennifer Cargile on Managing Cancer-Related Cognitive ImpairmentJennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.
Latest:
Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCLAdding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.
Latest:
Liquid Biopsies Are More Feasible, Appropriate for ESR1+ Breast CancerUsing liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.
Latest:
Oncology Therapy at the End of Life: Have We Missed the Mark?"Over the last decade, the landscape of systemic anti-cancer therapy has changed dramatically following the approvals of multiple new targeted therapies," - Kerin Adelson, MD.
Latest:
Oncology Drug Crash Course: Elacestrant (Orserdu)Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.
Latest:
Charina Toste Discusses the Educational Obstacles Patients With MPNs FaceAccording to Charina Toste, DNP, APRN-C, AOCNP, MSN, BSN, RN, patients with newly diagnosed myeloproliferative neoplasms may be unaware of the questions they should be asking their providers.
Latest:
Education Reassures Patients With MM Receiving Subcutaneous DaratumumabEducation before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse events, according to Stephanie Mompoint, APRN.
Latest:
Advanced Practice Providers May Hold the Key to Improving Community Clinical Trial InvolvementSeventy-three percent of advanced practice providers reported that they are interested in becoming more involved with clinical trials.
Latest:
The Road Ahead: Future Directions in Metastatic Melanoma TreatmentPanelists discuss the importance of effective communication and multidisciplinary collaboration in managing immunotherapy toxicities and ensuring seamless patient care, while highlighting promising advances in melanoma treatment and the role of telehealth and community outreach in expanding access and improving outcomes.
Latest:
Is a Health Care Price Transparency Revolution at Hand?The Transparency in Coverage Final Rule requires health care payers to unveil all previously secret negotiated prices with in-network providers.
Latest:
Bridging Communication Gaps: Comprehensive Care for Upper GI Cancer TreatmentExperts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.
Latest:
Referral Process With Bispecifics: Challenges and SupportDr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for bispecific therapy, including local health care barriers, and strategies for ensuring consistent patient education and support when care is shared between community and academic centers.
Latest:
Optimizing Multidisciplinary Care for ESR1-Mutated Breast Cancer: Strategies and Future DirectionsPanelists discuss strategies for medication adherence and patient education, emphasizing the importance of proactive communication and support from the entire health care team.
Latest:
Referral Process With Bispecifics: Challenges and SupportDr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for bispecific therapy, including local health care barriers, and strategies for ensuring consistent patient education and support when care is shared between community and academic centers.
Latest:
Support Systems and Multidisciplinary Treatment ApproachPanelists discuss City of Hope’s multidisciplinary approach, highlighting pharmacists providing medication guidance, social workers offering emotional support, and palliative care specialists managing symptoms, while consultants such as cardiologists and infectious disease experts address specific health issues to ensure coordinated, personalized care; complementary therapies such as acupuncture and mindfulness help manage adverse effects like neuropathy, and support groups foster community and resilience among patients and caregivers throughout their myeloma journey.
Latest:
Integrated Behavioral Health Vs Standard Practice: What’s The Difference?A licensed clinical health psychologist with Allegheny Health Network discusses fully integrated behavioral health programs and how their design alleviates potential barriers to care that patients may experience.
